OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
P/B ratio for OptiNose, Inc. (OPTN)
P/B ratio as of 2023: -1.67
According to OptiNose, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -1.67. At the end of 2022 the company had a P/B ratio of -2.81.
P/B ratio history for OptiNose, Inc. from 2015 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | -1.67 |
| 2022 | -2.81 |
| 2021 | -4.23 |
| 2020 | 29.44 |
| 2019 | 6.27 |
| 2018 | 2.08 |
| 2017 | 1.35 |
| 2016 | -132.26 |
| 2015 | -18.70 |